← All trials
NCT00145769
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2001
- Primary completion
- Jun 30, 2009
- Completion date
- May 31, 2011
- First posted
- Sep 5, 2005
- Last posted
- Aug 9, 2013
- Enrollment
- 326
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Trans Tasman Radiation Oncology GroupLead sponsor
- Australasian Gastro-Intestinal Trials GroupCollaborator
- Peter MacCallum Cancer CentreStudy chair
- Peter MacCallum Cancer CentreOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.